www.emcdda.eu.int

EMCDDA Work Programme for 2005

(Document EMCDDA/39/04 FINAL adopted by the EMCDDA Management Board at its meeting of 19-21/01/05)

Document: EMCDDA/39/04 FINAL

EMCDDA 2005 Work Programme

Summary

The proposed EMCDDA work programme (WP) for 2005 continues the implementation of the EMCDDA three year work programme (2004-2006) and therefore necessarily reflects the structure of the longer term strategy. (see EMCDDA/29/03).
In particular; the 2005 WP will consolidate the work to integration the new Member States in the EMCDDA structures and activities, continue the core work to improve information tools to better monitoring and report on the European drug situation, and further develop an improved information management capacity in the EMCDDA by investing in the development of a more efficient system for information storage and retrieval.

In 2005 the EMCDDA will therefore focus its work on the following priority areas:

1. **Core tasks essential to the implementation, development and maintenance of the existing instruments and mechanisms for data collection and analysis in the enlarged EU, in accordance with the working framework and the content of the adopted EMCDDA 2004-2006 WP.** In this context a special attention will be given to :
    - **a.** the full incorporation of the concerned actors of the new EU Member States in the EMCDDA activities, while consolidating the conditions for data monitoring and analysis, particularly with regard to the implementation of the REITOX reporting system;
    - **b.** the support to the candidate countries (Bulgaria, Romania and Turkey) for their participation in the EMCDDA activities within the framework of the EU pre-accession strategy and in accordance with the relevant EU instruments (PHARE) and agreements with the concerned countries.
    - **c.** on going- work necessary to support member in meeting their reporting tasks, the continued refinement of reporting tools and a high quality analysis of the EU drug situation.

2. **Consolidation and further development of the EMCDDA data storage and retrieval system for quantitative and qualitative information reported by the national focal points** and other relevant information providers. The system will serve the strategic needs of the EMCDDA in data collection, information management and dissemination channels. It will integrate, as much as possible, the existing data collection tools, databases and web sites. From a technical point of view, it will be based on the EMCDDA IT-infrastructure and reflect the methodological needs of handling the information sets required for the EMCDDA key task of reporting on the drug situation.

3. **Improvement of the EMCDDA data reporting and dissemination on the drug phenomenon.** In this context the EMCDDA will continue to promote an integrated approach to reporting, work to improve the analytical quality of its outputs and produce products targeted on identified key information needs and audiences. To achieve this more effectively in 2005 work is proposed to streamline and rationalise the multilingual policy for data dissemination.

Respecting the decision taken by the EMCDDA Management Board on the REITOX operating framework, the REITOX Focal Points have been involved from an early stage in the preparation of this document.
In accordance with article 8 of the EMCDDA founding regulation, the EMCDDA Scientific Committee and the European Commission have been formally consulted..

Budgetary effect

The budgetary resources required for the implementation of the proposed 2005 WP will be provided by the EMCDDA budget for 2005, as adopted by the Management Board.

EMCDDA 2005 work programme

TABLE OF CONTENTS

I. FOUNDATIONS OF THE 2005 WORK PROGRAMME

The EMCDDA work programme (WP) for 2005 continues the implementation of EMCDDA three year WP for 2004-2006. It is consistent with the foundations and content of this one (see EMCDDA/29/03) and it is subject to the decision of the budgetary authority providing the necessary resources under the 2005 budget.

As a consequence the 2005 WP, within the limits of the available budget for 2005, aims particularly at consolidating the integration of the new Member States in the EMCDDA structures and activities, while consolidating the EMCDDA core work to monitoring the drug situation supported by the implementation of an enhanced system for information storage and retrieval.

In this context the 2005 WP is also consistent with the underlying principles of the 2004-2006 WP and particularly with the objectives aiming at improving the quality and effectiveness of the EMCDDA work and promoting an output-driven and objective-focused approach. These objectives include:

- Improving scientific standards and quality.
- Improving the visibility and recognition of the EMCDDA
- A focus on core priorities, ensuring that the resources available are invested to maximum effect
- Ongoing evaluation the relevance of the EMCDDA objectives and outputs, with special attention to the key indicators
- The development of the internal synergies necessary to optimise in-house knowledge, expertise and resources.
- A focus on products to meet identified information needs and reflecting the needs of key audiences
- Increase networking activities to draw out the potential of partners' information resources and expertise.
- Better Integration and synergy of the work of the EMCDDA work with key partners, the European institutions and bodies, and appropriate international organisations.

II. WORKING FRAMEWORK PRIORITIES AND OBJECTIVES FOR 2005

II.A. THE WORKING FRAMEWORK

The working framework for 2005 is reflected in the enclosed thematic matrix (see Annex 1) and is consistent with the matrix of the EMCDDA 2004-2006 WP.

This matrix is consistent with the EMCCDA mission and mandate, as defined in the existing relevant EU regulations, without prejudicing any development that could be entailed by the forthcoming amendment of the EMCDDA founding regulation and by decision replacing and revising of the EU Joint Action on new synthetic drugs.

The matrix presents:

- the operational areas where the EMCDDA will focus its work, which reflect the content of the EMCDDA four core programmes, in accordance with the project-based working methods and organisation adopted by the Centre (Monitoring of the situation of the drug phenomenon; Monitoring of the responses, Monitoring national and community strategies and policies and their impact on the drug situation; Implementing the EU Joint Action on new synthetic drugs);

- the topics on which the EMCDDA will focus its activities, namely through the conception implementation or/and exploitation of a limited set of indicators and core data, by means of specific projects, as outlined in the EMCDDA work programme for 2004-2006;

- the links to the targets of the EU strategy on drugs, while ensuring the flexibility required to enable the Centre to cope with the EU future relevant priorities and any eventual change that the results of the expected amendment of the EMCDDA founding regulation could require in the EMCDDA mission and mandate.

In the fields where the EMCDDA mainly relies on data which are collected and produced by other organisations (such as EUROPOL, INTERPOL, United Nations Office on Drugs and Crime-UNODC) the Centre will explore to the maximum the opportunities for co-operation with these bodies.

These fields concern mostly the supply reduction-related aspects of the drug phenomenon and reflect a lower level of priority for the EMCDDA, particularly in terms of allocation of resources.

In this areas the EMCDDA activities will be based on the conceptualisation work conducted under the 2001-2003 work programme taking into account the need to provide a comprehensive overview of the drugs situation and the desirability of developing new themes or exploiting existing ones.

II.B. THE PRIORITIES FOR 2005

Within the referred thematic working framework, in 2005 the EMCDDA will focus its work on the following priorities:

1. **Core tasks essential to the implementation, development and maintenance of the existing instruments and mechanisms for data collection and analysis in the enlarged EU, in accordance with the working framework and the content of the adopted EMCDDA 2004-2006 WP.** In this context a special attention will be given to :

   a. the full incorporation of the concerned actors of the new EU Member States in the EMCDDA activities, while consolidating the conditions for data monitoring and analysis, particularly with regard to the implementation of the REITOX reporting system;
   b. the support to the candidate countries (Bulgaria, Romania and Turkey) for their participation in the EMCDDA activities within the framework of the EU pre-accession strategy and in accordance with the relevant EU instruments (PHARE) and agreements with the concerned countries.
   c. on going work necessary to support member in meeting their reporting tasks, the continued refinement of reporting tools and a high quality analysis of the EU drug situation.

2. **Consolidation and further development of the EMCDDA data storage and retrieval system for quantitative and qualitative information reported by the national focal points** and other relevant information providers. The system will serve the strategic needs of the EMCDDA in data collection, information management and dissemination channels. It will integrate, as much as possible, the existing data collection tools, databases and web sites. From a technical point of view, it will be based on the EMCDDA IT-infrastructure and reflect the methodological needs of handling the information sets required for the EMCDDA key task of reporting on the drug situation.

3. **Improvement of the EMCDDA data reporting and dissemination on the drug phenomenon.** In this context the EMCDDA will continue to promote an integrated approach to reporting, work to improve the analytical quality of its outputs and produce products targeted on identified key information needs and audiences. To achieve this more effectively in 2005, work is proposed to streamline and rationalise the multilingual policy for data dissemination.

II.C. THE MAIN OBJECTIVES AND ACTIVITIES FOR 2005

The main objectives and activities of each EMCDDA programme will be oriented in accordance with the above-mentioned 2005 priorities and the referred thematic working framework (matrix).

As a consequence**, the main objectives and activities relating to the four EMCDDA core programmes are presented <u>here below</u>.**

The contribution of the REITOX to the implementation of the EMCDDA 2005 WP (EMCDDA REITOX Co-ordination activities and tasks of the National Focal Points) is presented in **<u>Annex 2 herewith</u>.**

The specific objectives and activities concerning the EMCDDA Communication and data Dissemination, are presented in **<u>Annex 3 herewith</u>**

II.C.1. Main 2005 objectives and activities for the monitoring of the Situation (Programme P1)

1. Objectives and activities relating to basic essential core tasks

To a large extent 2005 needs to be a year of consolidation for this area of activity. In terms of both products and processes, a number of areas initiated in 2004 will only be completed or begin to deliver their intended benefits in the course of the 2005 work programme.

All developments are likely to be slow, and at risk, as simply the demands of dealing with the core tasks generated by the enlarged workload with the envisaged resource restrictions means that very little spare capacity exists for developmental activities once the routine reporting needs have been addressed.
In this context a key objective will be to facilitate the new member states to provide data and encourage all member states to collect and submit data in accordance with the indicator guidelines.

2. Implementation of the data storage and retrieval system

The reporting priorities rest upon the efficiency by which data can be managed and the appropriateness of the data collected to reporting needs. Key here is the overall priority to develop an information storage and retrieval system. As quantitative epidemiological data will play a central role in this system, a key objective will remain in 2005 to move the reporting tools online and to continue to rationalise them taking into account information needs.

To ensure data coverage of key reporting areas attention will also be given to the continued rationalisation of the I) crime and supply tables and II) for the direct inclusion of the data from the European School Survey Project on Alcohol and Other Drugs (ESPAD) into the EMCDDA system (a high priority) and III) for a one-off analysis and rationalisation of the data on infectious diseases.

In addition, the work begun on the refocusing of the problem drug use indicator in 2004 will need to be continued in 2005. This indicator is a key information domain for the EMCDDA and the reporting tools appear insufficient to address today's drug situation. Reinvigorating this indicator is therefore an important priority even if only modest progress can be expected in short-term.

3. Reporting/Data dissemination on the drug phenomenon

A key objective for 2005 will simply be to ensure that the increased volume of data coming from the member states is cleaned, processed and analysed in a timely fashion and results in high quality annual outputs (Annual Report & supporting statistical bulletin and others).

Another key objective will be to improve the quality of the statistical bulletin, its analytical content and improving its synergy with other EMCDDA products.

II.c.2. Main 2005 objectives and activities for the monitoring of the Responses (Programme P2)

1. Objectives and activities relating to basic essential core tasks

In 2005, several Standard questionnaires will be implemented, assessed or developed, thereby completing the scope of working areas relating to the monitoring of the responses.
The managers' network for the database on Exchange on Drug Demand Reduction Action (EDDRA) will be constantly monitored and animated, and a survey on policy makers' needs for information on 'best practice' will be conducted on demand of the EMCDDA Management Board.
The cooperation with the World Health Organisation (WHO) will be pursued in the field of prison and health with a joint questionnaire and a survey planned in 2006 on health and social measures and interventions targeting drug users in prisons, and on co-morbidity and mental health in relation to the WHO Ministerial Conference on Mental Health and the following Action Plan on Mental Health.
The EMCDDA will continue to contribute to the Pompidou Group Platform on ethics. The newly started cooperation with the International Red Cross will be followed up. In the area of supply reduction, relations with the UNODC, Europol, Interpol, World Customs Organisation (WCO) and Financial Action Task Force on Money Laundering (FATF) should be consolidated and lead to concrete information exchange.

2. Implementation of the data storage and retrieval system

In order to integrate EDDRA in the new data storage and retrieval system, and to follow-up developments in 2004-2005 (revised questionnaire, new Member States), the preparation of an updated off-line tool, database and website for EDDRA will continue.
With the introduction of Standard Tables and Structured Questionnaires, the EMCDDA will proceed in establishing on-line interfaces for the questionnaires with dynamic database connection to substitute excel- and word-files.
The compatibility of a joint database EMCDDA - WHO will be assessed, within the framework of their co-operation in collecting and disseminating information on health and social measures and interventions targeting drug users in prisons.
Preliminary work on including supply reduction information into the data storage and retrieval system will be undertaken.

3. Reporting/Data dissemination on the drug phenomenon

The Annual Reporting exercise will be more structured and extensive, and include the EMCDDA Annual Report, on-line tables, graphics and maps, selected issue on alternatives to prison, inclusion of selected tables in the EMCDDA Statistical Bulletin, and in-depth thematic country profiles, based on Standard Questionnaires (SQ) and other information. EDDRA will complete the picture of demand reduction interventions in the EU.
Thematic analyses on specific topics will be prepared, e.g. on universal prevention, needle and syringe-exchange programmes and other issues on reduction of drug-related harm, and on assistance to drug users in prisons, as well as inputs to the planned monograph on cannabis.
Contributions to policy briefings will be submitted according to planning.
The websites related to responses will be restructured, constantly up-dated and extended with new material and analyses.
Training and quality assurance of interventions, especially on prevention and reduction of drug-related harm, will receive particular attention. Sustaining and developing the Evaluation Instrument Bank (EIB) will be part of the training and quality assurance task.

II.C.3. Main 2005 objectives and activities for the implementation of the Early Warning System and Risk Assessment of new (synthetic) drugs (Programme P3)

1. Objectives and activities relating to basic essential core tasks

The EMCDDA will ensure the accomplishment of its tasks for the implementation of the Early Warning System and Risk Assessment of new synthetic drugs, in accordance with the 1997 Joint Action on new synthetic drugs as well as the (expected) new tasks assigned to the Centre by the Council Decision on the information exchange, risk-assessment and control of new psychoactive substances.

In this context the EMCDDA will operate to ensure that the Early Warning System and the Risk Assessment procedures are rapidly adapted to the extended scope, modus operandi and reporting requirements of the new Council Decision. This includes the following:

- review of the internal and external working methods (timing and sequencing of actions);
- revision of the Early Warning System Guidance document;
- initial revision of the Guidelines for Risk Assessment of new drugs (in cooperation with the Scientific Committee);
- revision of three main monitoring and reporting tools: *EMCDDA-Europol Reporting form*; the *EMCDDA-Europol Joint Report* (both in cooperation with Europol); and the *Early Warning System Progress Report template* (in cooperation with the REITOX National Focal Points);
- preparation of a format and the first EMCDDA/Europol Annual Report on the implementation of the new Council Decision to be submitted by to the Council, the Parliament and the Commission.

The EMCDDA will ensure that its specific tasks stipulated by the means of the new Council Decision are given high priority within its cooperation with the concerned EU Institutions (the Commission, the Council, Europol, the European Medicines Agency-EMEA) and as well as within the impending EU Drug Strategy and corresponding Action Plan.

Furthermore, the EMCDDA will strive to ensure enhanced involvement and commitment of the REITOX network partners. This will entail special attention to the needs and realities of the new Member States and the candidate counties.

2. Implementation of the data storage and retrieval system

The work launched in 2004 will be pursued in 2005 for the development and operationalisation of an evidence-based database on new (synthetic) drugs, dynamically linked to both the EMCDDA public website and the newly created Joint Action extranet. The focus will be on designing and testing of the database and entering the data.

3. Reporting/Data dissemination on the drug phenomenon

The EMCDDA new (synthetic) drugs website will be developed and made available to the public as a part of the EMCDDA web environment, presenting all outputs resulting from the implementation of the 1997 EU Joint Action on new synthetic drugs and the expected new Council Decision and the REITOX Early Warning System and providing links to other appropriate web information and resources.

II.C.4. Main 2005 objectives and activities for the monitoring national and community strategies and policies and their impact on the drug situation – Contribution to the evaluation of the EU action plans (Programme P4)

1. Objectives and activities relating to basic essential core tasks

The year 2005 will be mainly dedicated to the consolidation of the work and activities carried out in 2004, namely with regard to: National Drug policies and coordination, National and European Legislation, Contribution to the evaluation of the EU action and Treatment and Social Rehabilitation.
In each of those areas, efforts will be made to improve and streamline the data collection process (conceptualisation, launch, test, implementation of Structured questionnaires and standard tables) and to develop cooperation, when appropriate, with relevant partners (like UNODC on legislations).
Efforts to improve the management of the legal correspondent (LC) network will be continued (meeting formula improved, rationalised data collection and study reviewing processes).
Focus will also be kept on supporting the development of the future evaluation exercises of the EU action plans and on improving methodological tools and processes for future evaluation (in particular improvement of the *snapshot* structure and contents and its synergy with the Annual Report and Statistical bulletin).

Due to budgetary constraints, there will be little room for developmental activities, particularly for the public expenditure project, for which conceptual work will be strictly adapted to available resources (assessment of the feasibility and the usefulness of economic drug related indicators and preliminary work on possible data collection tools) and for activities relating to law implementation/enforcement, where only preliminary work will be carried out.

2. Implementation of the data storage and retrieval system

The work already started in 2004 for defining data storage and retrieval needs will be continued in 2005, with special attention to the identification and organisation of collected data with regard to relevant products and website interfaces. This includes implementation of new reporting tools, data processing (cleaning, sorting and inserting) and up-dating, restructuring and development of the EMCDDA relevant website areas (in particular implementation of the a new structure and products for the European Legal Database on Drugs-ELDD). This also implies integrating relevant products and databases (essentially *Snapshot*, ELDD and the Evaluation Instrument Bank-EIB) in the main system architecture.

3*. Reporting/Data dissemination on the drug phenomenon*

- As in 2004, there will be three main targets in 2005: 1) Improve the contribution to the Annual report, to the Selected issue and related products; 2) Exploit already available data and disseminate results on several thematic issues, in particular on policy developments, coordination implementation, laws and legislation (topic overviews, study on money laundering) and treatment (cannabis)), as well as contribute to the planned Cannabis Monograph; 3) Up-date existing on-line products and studies (like legal comparative studies and report on coordination mechanisms).

III. RESOURCES AND MEANS

The budgetary resources required for the implementation of the WP 2005 will be provided by the 2005 Budget of the EMCDDA, as adopted by its Management Board.

- ***The EC annual subsidy on which the EMCDDA budget for 2005 will rely is expected to amount to12.000.000 €*** *reflecting a substantial stagnation compared with 2004. In this context, further to the need to focus available resources on the above mentioned 2005 priorities, a special attention will be paid to the following aspects:*

- **the EMCDDA will pursue its effort to improve internal efficiency**, further improving its organisation and working methods so as to be in a better position to meet its objectives while coping with budgetary constraints.

- **Strategic partnerships** based on the recognition of shared competence, complementarity and subsidiarity will be strengthened, with special attention to:

  - better integrated partnerships with European institutions and bodies (Parliament, Council, Commission);

  - further collaborative partnerships with the REITOX, with special attention to the implementation of the reporting instruments and to the data quality;

  - improved cooperation with the EMCDDA partner organisations (Europol, WHO, Pompidou Group, UNODC, INTERPOL, Customs Cooperation Council-CCC)

  - cooperation with selected organisations for specific activities (like Inter-American Drug Abuse Control Commission-CICAD, World Customs Organisation-WCO, International Red Cross, European University Institute of Florence);

- **The provision of sufficient resources for the consolidation and further development of the EMCDDA data storage and retrieval system,** ensuring the availability of a proven capacity for data management to steer the development and implementation of the data storage and retrieval system, acting as an interface with regard to the different EMCDDA concerned actors (scientific, IT, data dissemination, REITOX coordination staff and REITOX national focal points).

- **Specific adequate supplementary resources will be necessary for any eventual new/additional activity, operation or development** entailed by the expected modification of the EMCDDA founding regulation, the forthcoming decision on the Early Warning System and Risk Assessment of new (synthetic) drugs, the new EU drugs strategy and action plan.

ANNEX 1

Matrix for 2005 WP

EU TARGET	MONITORING OF THE SITUATION	MONITORING OF THE RESPONSES
T1 Reduce prevalence of illicit drug use, as well as new recruitment, especially among young people	Drug use in general population : prevalence data from general population and school surveys (ki) Prevalence of problem drug use: estimates and statisticals models (ki) Emerging trends and drug use among young people and at risk groups (cd)	Universal prevention of drug use (cd) Selective/indicated prevention of drug use (cd)
T2 Reduce incidence of drug-related health damage and drug-	Infectious diseases among drug injectors (ki) Drug related death and drug mortality over time (ki)	Prevention of drug related infectious diseases (cd) Prevention of drug related deaths (cd)
T3 Increase number of successfully treated addicts	Treatment demand (ki)	Drug-related treatment (cd) Social reintegration(cd)
T4 Reduce drug related crime	Crimes against the drug legislation: drug law offendes/offenders (cd) Crimes related to drug use: crimes under the drug influence and acquisitive crimes (cd) Drug use among criminal populations: prevalence of drug users in prison (cd)	Assistance to drug users in prisons (cd) Alternatives to prison (cd)
T5 Reduce availability of illicit drugs	Drug seizures, drug prices,and purity at retail level, including contents of 'ecstasy' tablets (cd) Origin/destination of drugs, trafficking routes, patterns and groups (cd) Drug availability/access (cd)	*Interdiction measures*
T6 Reduce money laundering and illicit trafficking of		*Anti money laundering measures* *Measures against the diversion of chemical precursors*
IMPLEMENTING EU JA ON NEW SYNTHETIC DRUGS Data resulting from the Early Warning System (art.3 JA) and from the Risk assessment of NSD (art.4 JA)		
National and Community strategies and policies (T1, T2, T3, T4, T5, T6) EU ACTION PLAN 2000 – 2004	**MONITORING NATIONAL AND COMMUNITY STRATEGIES AND POLICIES AND THEIR IMPACT ON THE DRUG SITUATION – CONTRIBUTION TO THE EVALUATION OF THE EU ACTION PLANS** - political and institutional framework including coordination arrangements (EU and national) (cd) - legal framework and practice in general (EU and national) (cd) - policy implementation (EU and national) (cd); - Public expenditure and funding arrangements (EU and national) (cd) - Snapshots and baselines (pi)	

ki = formally agreed 5 key indicators cd = core data pi = performance *indicators*

Italic and grey font indicate where the EMCDDA mainly relies on data which are primarily collected and produced by other organisations.

ANNEX 2

REITOX contribution to the implementation of the EMCDDA 2005 WP (REITOX Coordination and National Focal Points activities)

EMCDDA 2005 ACTIVITY FOR REITOX COORDINATION

- Managing and further developing the Reitox network of EMCDDA partners according to the 'Operating framework of the Reitox system (e.g. full implementation of the new Reitox reporting structure', deepening the cooperation between old and new Member States)
- Assessing the quality of the reports, data and information received in 2004. Reviewing the current quality approach (guidelines, assessment and feedback) for National Reports and Standard Tables and developing a new one for Structured Questionnaires.
- Further developing the role of the Reitox/Enlargement team as the interface between the Member States and the EMCDDA scientific and IT departments in view of the implementation of the Data Storage and Retrieval System and the enhancing of reporting and data dissemination. Acting according to the defined role.
- Drafting and publishing Country Situation Summaries for the Candidate Countries. Reviewing the structure of the Country Situation Summaries and launching the updating of the existing ones.
- Preparing and managing assistance to Bulgaria and Romania (new Phare project).
- Accompanying the Candidate Countries on their way towards EMCDDA membership and managing their integration into the EMCDDA work and bodies.

TASKS OF THE REITOX NATIONAL FOCAL POINTS FOR 2005

(as defined in the draft 2005 REITOX agreements)

Collection and analysis of information at national level in 2005:

- Annual national report;
- Statistical standard tables and structured questionnaires;
- Data requested within the implementation of the epidemiological key indicators;
- Data input into EDDRA database and the REITOX extranet;
- Joint action on new synthetic drugs: early warnings to the EMCDDA;
- Updates regarding national developments, e.g. operational, legal, institutional and political changes and events [1];
- Press clippings covering major national developments as well as EMCDDA and/or NFP events, e.g. launch of the Annual Report [1];
- Replies to ad hoc requests from the EMCDDA [1].

Dissemination at national level:

- Distribution of EMCDDA reports and other products;
- Joint action on new synthetic drugs: information from the EMCDDA to national partners;
- Media relations at national level;
- Informing relevant national partners and network(s) about quality feedback provided by the EMCDDA;
- Responding to queries at national level or, where indicated, channelling such requests to the EMCDDA. Being the EMCDDA's 'ambassador' at national level [2];
- Language checking and proof-reading of EMCDDA products [2];

Progress reports on the implementation of:

- The epidemiological key indicators at national level;
- The EU joint action on new synthetic drugs at national level;
- EDDRA and REITOX information systems.

[1] When information requested is not readily available, the beneficiary is expected (within the limits of its resources' availability) to make reasonable efforts to obtain this information.
[2] The beneficiary is expected to make reasonable efforts in these particular areas, within the limits of its resources' availability.

ANNEX 3

2005 objectives and activities for the EMCDDA communication and data dissemination

1. Overall communication strategy: Redefine, adopt and implement a global communication strategy taking into account the general context of drugs within EU institutions, the priorities and objectives of the EU strategy and Action plan on drugs and the existing budgetary constraints, while streamlining and rationalising the EMCDDA multilingual policy for data dissemination.

2. Products: produce and improve the quality of the following products, while :

    2.1 **Annual reporting package:** Annual report on paper + Annual report online + Selected issues + Statistical bulletin + Country situation summaries**.**

    2.2 **Website**: refreshing, reorganising (e.g. into thematic domains) and maintaining the website as the main communication tool of the EMCDDA.

    2.3 **Policy briefings**: three editions in 2005 (themes still to be determined).

    2.4 **Newsletter**: conceptualising and implementing a new approach according to current circumstances.

    2.5 **Other outputs**: 1 monograph on Cannabis, Thematic analyses (e.g. on universal prevention, needle and syringe-exchange programmes), Scientific reports (e.g. Impact of law changes), comparative studies, grey literature.

ANNEX 4

Structure and content of the 2005 Annual Reporting on the State of the Drug Phenomenon in the European Union

A. Annual report (printed version)

The aim is to produce a printed report (to be published in 20/21 languages) of about 70 pages. (This is the length of the 2004 report without the selected issues.)

Proposed structure and contents for the 2005 Annual report

Foreword
Acknowledgements
Introductory note including diagram on the various products available and the type of information that can be found in each of them
Policy • What is new in the areas of strategies and policies – transversal e.g. in harm reduction policy, prevention policy, treatment policy as well as EU and national policy
Drugs • Cannabis • Cocaine and crack cocaine • Amphetamine-type stimulants, other synthetic drugs • Heroin and injecting drug use • Polydrug use
Other developments • Schools, youth and drugs • Treatment • Crime and prison issues
Summary of selected issues (The complete selected issues will be produced as a separate publication and published in English only). • Buprenorphine • Public nuisance • Alternatives to prison for drug using offenders
References
Reitox focal points

B. Selected issues (separate publications)

Introduction
• Buprenorphine • Public nuisance • Alternatives to prison for drug using offenders
References

Format: A4, similar style as the Annual report. Produced in English.

C. Statistical bulletin (http://statistics.emcdda.eu.int)

The bulletin is a companion publication to the EMCDDA annual report and provides a complementary information source. It supplies the user with the data tables collated by the EMCDDA from the information submitted by the national focal points Reitox network. These tables constitute the epidemiological basis on which the annual report is written and are frequently referenced by it. In addition to the tables of data and the accompanying graphics, the bulletin gives detailed technical commentaries, notes and descriptions.

Format: On-line publication. Content:

- About 100 statistical tables on the drugs situation (P1)
- Methodological notes
- Country data sheets
- Commentary and analysis

D. Annual report – online version (http://annualreport.emcdda.eu.int/)

20/21 language versions of the printed document produced in html format with supplementary links to a set of core diagrams and tables that are updated annually as a matter of course. These elements may be located in thematic website areas in the main EMCDDA site rather than integrated into the Annual report website itself.

E. Country situation summaries (http://profiles.emcdda.eu.int/)

The Country situation summaries provide brief synopses of up-to-date national data and trends. While they are conceived as more durable products to be updated on an ongoing basis, they do form a part of the reporting package.